{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:53:08Z","timestamp":1787500388916,"version":"build-2736575974"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"13","license":[{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"FSHD Society","award":["FSHS-82016-03"],"award-info":[{"award-number":["FSHS-82016-03"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Facioscapulohumeral muscular dystrophy (FSHD) is a prevalent, inherited skeletal myopathy linked to hypomethylation of the D4Z4 macrosatellite at chromosome 4q35. This epigenetic de-repression permits expression of the transcription factor DUX4, which may drive pathology by direct activation of target genes or through inhibition of the homologous transcription factor PAX7. We demonstrated that PAX7 target gene repression is a superior biomarker of FSHD status compared with DUX4 target gene expression. However, despite importance for clinical trials, there remains no transcriptomic biomarker for FSHD progression. A recent study by Wong et\u00a0al. [Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies. Hum. Mol. Genet., 29, 1030\u20131043] performed MRI, muscle biopsy transcriptomics and histopathology on a cohort of FSHD patients with 1-year follow-up. No significant changes in any biomarkers were reported over this time period. However, the authors did not consider PAX7 target gene repression as a marker of FSHD progression. Here we demonstrate that PAX7 target gene repression increases in these paired FSHD samples from year 1 to year 2 and is thus a marker of FSHD progression over 1 year. Moreover, we show that three validated DUX4 target gene expression biomarkers are not associated with FSHD progression over 1 year. We further confirm that PAX7 target gene repression associates with clinical correlates of FSHD disease activity, measured by MRI and histopathology. Thus, PAX7 target gene repression is a uniquely sensitive biomarker of FSHD progression and pathology, valid over a 1 year time frame, implicating its use in clinical trials.<\/jats:p>","DOI":"10.1093\/hmg\/ddaa079","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T07:08:39Z","timestamp":1587971319000},"page":"2124-2133","source":"Crossref","is-referenced-by-count":27,"title":["PAX7 target gene repression associates with FSHD progression and pathology over 1 year"],"prefix":"10.1093","volume":"29","author":[{"given":"Christopher R S","family":"Banerji","sequence":"first","affiliation":[{"name":"King's College London, Randall Centre for Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, London SE1 1UL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,29]]},"reference":[{"key":"2020112601263969500_ref1","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1212\/WNL.0000000000000797","article-title":"Population-based incidence and prevalence of facioscapulohumeral dystrophy","volume":"83","author":"Deenen","year":"2014","journal-title":"Neurology"},{"key":"2020112601263969500_ref2","first-page":"167","volume-title":"Handbook of Clinical Neurology","author":"Orrell","year":"2011"},{"key":"2020112601263969500_ref3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.nmd.2020.03.001","article-title":"Facioscapulohumeral muscular dystrophy 1 patients participating in the UK FSHD registry can be subdivided into 4 patterns of self-reported symptoms","volume":"30","author":"Banerji","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"2020112601263969500_ref4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/mus.26474","article-title":"Phenotype may predict the clinical course of facioscapolohumeral muscular dystrophy","volume":"59","author":"Ricci","year":"2019","journal-title":"Muscle Nerve"},{"key":"2020112601263969500_ref5","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/ene.13509","article-title":"Clinical and genetic features of patients with facial-sparing facioscapulohumeral muscular dystrophy","volume":"25","author":"He","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"2020112601263969500_ref6","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1007\/s00415-016-8123-2","article-title":"A novel clinical tool to classify facioscapulohumeral muscular dystrophy phenotypes","volume":"263","author":"Ricci","year":"2016","journal-title":"J. Neurol."},{"key":"2020112601263969500_ref7","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.bbadis.2014.05.021","article-title":"Facioscapulohumeral muscular dystrophy","volume":"1852","author":"Sacconi","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"2020112601263969500_ref8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1212\/WNL.43.2.345","article-title":"Extreme variability of expression in monozygotic twins with FSH muscular dystrophy","volume":"43","author":"Tawil","year":"1993","journal-title":"Neurology"},{"key":"2020112601263969500_ref9","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1212\/WNL.0b013e3182a84140","article-title":"Clinical and genetic features of hearing loss in facioscapulohumeral muscular dystrophy","volume":"81","author":"Lutz","year":"2013","journal-title":"Neurology"},{"key":"2020112601263969500_ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000094248","article-title":"Facioscapulohumeral muscular dystrophy and occurrence of heart arrhythmia","volume":"56","author":"Trevisan","year":"2006","journal-title":"Eur. Neurol."},{"key":"2020112601263969500_ref11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.nmd.2011.02.002","article-title":"Retinal vascular disease and the pathogenesis of facioscapulohumeral muscular dystrophy. A signalling message from Wnt?","volume":"21","author":"Fitzsimons","year":"2011","journal-title":"Neuromuscul. Disord."},{"key":"2020112601263969500_ref12","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1189044","article-title":"A unifying genetic model for facioscapulohumeral muscular dystrophy","volume":"329","author":"Lemmers","year":"2010","journal-title":"Science"},{"key":"2020112601263969500_ref13","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ng.2454","article-title":"Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2","volume":"44","author":"Lemmers","year":"2012","journal-title":"Nat. Genet."},{"key":"2020112601263969500_ref14","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ajhg.2016.03.013","article-title":"Mutations in DNMT3B modify epigenetic repression of the D4Z4 repeat and the penetrance of facioscapulohumeral dystrophy","volume":"98","author":"Boogaard","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"2020112601263969500_ref15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/cge.13726","article-title":"Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy","volume":"96","author":"Greco","year":"2020","journal-title":"Clin. Genet."},{"key":"2020112601263969500_ref16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2044-5040-4-12","article-title":"Facioscapulohumeral dystrophy: the path to consensus on pathophysiology","volume":"4","author":"Tawil","year":"2014","journal-title":"Skelet. Muscle"},{"key":"2020112601263969500_ref17","doi-asserted-by":"crossref","first-page":"e1001181","DOI":"10.1371\/journal.pgen.1001181","article-title":"Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene","volume":"6","author":"Snider","year":"2010","journal-title":"PLoS Genet."},{"key":"2020112601263969500_ref18","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ajpath.2012.07.007","article-title":"Generation of isogenic D4Z4 contracted and noncontracted immortal muscle cell clones from a mosaic patient","volume":"181","author":"Krom","year":"2012","journal-title":"Am. J. Pathol."},{"key":"2020112601263969500_ref19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.devcel.2011.11.013","article-title":"DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy","volume":"22","author":"Geng","year":"2012","journal-title":"Dev. Cell"},{"key":"2020112601263969500_ref20","doi-asserted-by":"crossref","first-page":"e26820","DOI":"10.1371\/journal.pone.0026820","article-title":"The FSHD atrophic Myotube phenotype is caused by DUX4 expression","volume":"6","author":"Vanderplanck","year":"2011","journal-title":"PLoS One"},{"key":"2020112601263969500_ref21","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.nmd.2007.04.002","article-title":"The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein","volume":"17","author":"Kowaljow","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"2020112601263969500_ref22","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1038\/emboj.2008.201","article-title":"An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies","volume":"27","author":"Bosnakovski","year":"2008","journal-title":"EMBO J."},{"key":"2020112601263969500_ref23","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1242\/jcs.180372","article-title":"DUX4 induces a transcriptome more characteristic of a less-differentiated cell state and inhibits myogenesis","volume":"129","author":"Knopp","year":"2016","journal-title":"J. Cell Sci."},{"key":"2020112601263969500_ref24","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1093\/hmg\/ddu251","article-title":"DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle","volume":"23","author":"Yao","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"2020112601263969500_ref25","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/s41467-017-01200-4","article-title":"PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle","volume":"8","author":"Banerji","year":"2017","journal-title":"Nat. Commun."},{"key":"2020112601263969500_ref26","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/hmg\/ddz043","article-title":"PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level","volume":"28","author":"Banerji","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"2020112601263969500_ref27","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddaa053","article-title":"DUX4-expressing immortalised FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation","volume":"ddaa053","author":"Banerji","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"2020112601263969500_ref28","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/hmg\/ddaa031","article-title":"Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies","volume":"29","author":"Wong","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"2020112601263969500_ref29","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/hmg\/ddy364","article-title":"MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD","volume":"28","author":"Wang","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"2020112601263969500_ref30","doi-asserted-by":"crossref","first-page":"D991","DOI":"10.1093\/nar\/gks1193","article-title":"NCBI GEO: archive for functional genomics data sets\u2014update","volume":"41","author":"Barrett","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"2020112601263969500_ref31","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1093\/nar\/gkw141","article-title":"DUX4 recruits p300\/CBP through its C-terminus and induces global H3K27 acetylation changes","volume":"44","author":"Choi","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"2020112601263969500_ref32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/mus.24621","article-title":"Muscle pathology grade for facioscapulohumeral muscular dystrophy biopsies","volume":"52","author":"Statland","year":"2015","journal-title":"Muscle Nerve"},{"key":"2020112601263969500_ref33","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1212\/WNL.0000000000004647","article-title":"Adding quantitative muscle MRI to the FSHD clinical trial toolbox","volume":"89","author":"Mul","year":"2017","journal-title":"Neurology"},{"key":"2020112601263969500_ref34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.119.259663","article-title":"Clinically advanced p38 inhibitors suppress DUX4 expression in cellular and animal models of facioscapulohumeral muscular dystrophys","volume":"370","author":"Oliva","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2020112601263969500_ref35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13395-017-0134-x","article-title":"BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells","volume":"7","author":"Campbell","year":"2017","journal-title":"Skelet. Muscle"},{"key":"2020112601263969500_ref36","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00415-006-0432-4","article-title":"Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy","volume":"254","author":"Kooi","year":"2007","journal-title":"J. Neurol."},{"key":"2020112601263969500_ref37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12883-019-1452-x","article-title":"Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study","volume":"19","author":"Lorusso","year":"2019","journal-title":"BMC Neurol."},{"key":"2020112601263969500_ref38","doi-asserted-by":"crossref","first-page":"e38779","DOI":"10.1371\/journal.pone.0038779","article-title":"Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles","volume":"7","author":"Tasca","year":"2012","journal-title":"PLoS One"},{"key":"2020112601263969500_ref39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinformatics"}],"container-title":["Human Molecular Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/hmg\/advance-article-pdf\/doi\/10.1093\/hmg\/ddaa079\/33438960\/ddaa079.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/29\/13\/2124\/34544146\/ddaa079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/29\/13\/2124\/34544146\/ddaa079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T01:26:50Z","timestamp":1606354010000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hmg\/article\/29\/13\/2124\/5826788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,29]]},"references-count":39,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2020,4,29]]},"published-print":{"date-parts":[[2020,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/hmg\/ddaa079","relation":{},"ISSN":["0964-6906","1460-2083"],"issn-type":[{"value":"0964-6906","type":"print"},{"value":"1460-2083","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7,1]]},"published":{"date-parts":[[2020,4,29]]}}}